Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s
cancers by incidence. Explore our oncology-focused pipeline, dedicated to addressing the most
pressing challenges in cancer care.

Pipeline

We are pursuing a broad and deep pipeline with the potential to address 80 percent of the world’s cancers by incidence. Explore our oncology-focused pipeline, dedicated to addressing the most pressing challenges in cancer care.

Download full pipeline
Area of interest
Area of interest
Planned
Ongoing
Completed

Filters

Filter
Development phase
Phase 1 (23)
Phase 2 (11)
Phase 3 (8)
Molecule
BG-68501 (1)
BG-C137 (1)
BG-C477 (1)
BG-C9074 (1)
BG-T187 (1)
BGB-15025 (1)
BGB-16673 (1)
BGB-21447 (1)
BGB-24714 (1)
BGB-26808 (1)
BGB-30813 (1)
BGB-43395 (1)
BGB-45035 (1)
BGB-53038 (1)
BGB-58067 (1)
BGB-A3055 (1)
BGB-A445 (1)
BGB-B2033 (1)
BGB-B3227 (1)
BGB-C354 (1)
BGB-R046 (1)
Blinatumomab (1)
LBL-007 (1)
Pamiparib (1)
Sonrotoclax (1)
Tarlatamab (1)
Tislelizumab (2)
Umbrella (1)
Xaluritamig (1)
Zanidatamab (1)
Zanubrutinib (2)
Compound type
ADC (4)
Bi/Tri-specific (7)
mAb (5)
Protein degrader (2)
Small molecule (13)

1Amgen collaboration; BeiGene has China commercial rights. 2Ensem collaboration; BeiGene has global rights. 3DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. 4Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. 5Zymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. 6Amgen collaboration; BeiGene has development and commercialization rights in China. 7Amgen collaboration; BeiGene has development and commercialization rights in China. aIn combination with Zanubrutinib. bMay include: PD-1 mAb, LAG3 mAb, OX40 mAb, TIM3 mAb, HPK1 inhibitor. * Trial is listed on clinicaltrials.gov, but may not have subjects enrolled.